论文部分内容阅读
目的观察不同剂量厄贝沙坦治疗糖尿病肾病患者的临床效果。方法选取2013年1月-2014年2月在医院就诊并接受治疗的糖尿病肾病患者120例,按患者入院时间先后分为观察组和对照组各60例。观察组给予大剂量(300mg/d)厄贝沙坦治疗,对照组给予小剂量(150mg/d)厄贝沙坦治疗,对比2组患者治疗前后血压、血肌酐(Scr)、血尿素氮(BUN)、血清钾(K+)及尿微量白蛋白等指标水平。结果 2组患者治疗后尿微量白蛋白水平及血压均低于治疗前,Scr高于治疗前,且观察组患者治疗后尿微量白蛋白含量显著低于对照组,差异均有统计学意义(P<0.05)。治疗后2组患者血压及Scr、BUN、K+治疗前后对比无显著性差异(P>0.05)。2组患者治疗期间均无明显不良反应发生。结论大剂量厄贝沙坦治疗糖尿病肾病患者的治疗效果优于小剂量,能更加有效地保护患者肾脏结构及功能,缓解患者尿蛋白升高症状,且无明显不良反应,值得临床推广。
Objective To observe the clinical effects of different doses of irbesartan in patients with diabetic nephropathy. Methods A total of 120 patients with diabetic nephropathy who were treated and treated in the hospital from January 2013 to February 2014 were selected and divided into observation group and control group according to their admission time. The observation group received high dose (300mg / d) irbesartan, while the control group received low dose (150mg / d) irbesartan. The blood pressure, serum creatinine (Scr), blood urea nitrogen BUN), serum potassium (K +) and urinary microalbumin and other indicators. Results After treatment, urinary albumin level and blood pressure were lower in both groups than before treatment, Scr was higher than before treatment, and the content of urinary albumin in the observation group was significantly lower than that in the control group (P <0.05). There was no significant difference in blood pressure and Scr, BUN, K + before and after treatment between the two groups after treatment (P> 0.05). No significant adverse reactions occurred in the two groups during treatment. Conclusion High-dose irbesartan treatment of diabetic nephropathy in patients with better than small doses of treatment, can more effectively protect the structure and function of kidney in patients with relief of elevated urinary protein in patients with symptoms, and no adverse reactions, is worth clinical promotion.